Kuros Biosciences AG (KURN) - Total Assets
Based on the latest financial reports, Kuros Biosciences AG (KURN) holds total assets worth CHF107.21 Million CHF (≈ $135.55 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can Kuros Biosciences AG service its debt to assess how comfortably operating cash covers total debt obligations.
Kuros Biosciences AG - Total Assets Trend (2004–2025)
This chart illustrates how Kuros Biosciences AG's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Kuros Biosciences AG for net asset value and shareholders' equity analysis.
Kuros Biosciences AG - Asset Composition Analysis
Current Asset Composition (December 2025)
Kuros Biosciences AG's total assets of CHF107.21 Million consist of 61.1% current assets and 38.9% non-current assets.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 14.6% |
| Accounts Receivable | CHF31.85 Million | 29.7% |
| Inventory | CHF16.92 Million | 15.8% |
| Property, Plant & Equipment | CHF4.68 Million | 4.4% |
| Intangible Assets | CHF13.15 Million | 12.3% |
| Goodwill | CHF19.25 Million | 18.0% |
Asset Composition Trend (2004–2025)
This chart illustrates how Kuros Biosciences AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Kuros Biosciences AG worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kuros Biosciences AG's current assets represent 61.1% of total assets in 2025, a decrease from 76.1% in 2004.
- Cash Position: Cash and equivalents constituted 14.6% of total assets in 2025, down from 23.8% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 29.0% of total assets, an increase from 0.0% in 2004.
- Asset Diversification: The largest asset category is accounts receivable at 29.7% of total assets.
Kuros Biosciences AG Competitors by Total Assets
Key competitors of Kuros Biosciences AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Edwards Lifesciences Corp
NYSE:EW
|
USA | $13.32 Billion |
|
DexCom Inc
NASDAQ:DXCM
|
USA | $6.63 Billion |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
|
China | CN¥805.10 Million |
|
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
SHG:688212
|
China | CN¥1.86 Billion |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Theradiag SA
PA:ALTHE
|
France | €11.55 Million |
|
Corentec Co Ltd
KQ:104540
|
Korea | ₩175.16 Billion |
|
Adherium Ltd
AU:ADR
|
Australia | AU$4.16 Million |
Kuros Biosciences AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.96 | 2.14 | 8.76 |
| Quick Ratio | 1.45 | 1.69 | 8.39 |
| Cash Ratio | 0.00 | 0.00 | 7.32 |
| Working Capital | CHF32.11 Million | CHF23.86 Million | CHF30.09 Million |
Kuros Biosciences AG - Advanced Valuation Insights
This section examines the relationship between Kuros Biosciences AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.35 |
| Latest Market Cap to Assets Ratio | 7.07 |
| Asset Growth Rate (YoY) | 26.8% |
| Total Assets | CHF107.21 Million |
| Market Capitalization | $758.37 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Kuros Biosciences AG's assets at a significant premium (7.07x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Kuros Biosciences AG's assets grew by 26.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Kuros Biosciences AG (2004–2025)
The table below shows the annual total assets of Kuros Biosciences AG from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CHF107.21 Million ≈ $135.55 Million |
+26.82% |
| 2024-12-31 | CHF84.54 Million ≈ $106.88 Million |
+18.29% |
| 2023-12-31 | CHF71.46 Million ≈ $90.35 Million |
-13.84% |
| 2022-12-31 | CHF82.95 Million ≈ $104.87 Million |
-9.19% |
| 2021-12-31 | CHF91.34 Million ≈ $115.47 Million |
-3.21% |
| 2020-12-31 | CHF94.36 Million ≈ $119.30 Million |
+7.41% |
| 2019-12-31 | CHF87.85 Million ≈ $111.07 Million |
+2.37% |
| 2018-12-31 | CHF85.82 Million ≈ $108.50 Million |
-0.30% |
| 2017-12-31 | CHF86.08 Million ≈ $108.83 Million |
+96.68% |
| 2016-12-31 | CHF43.77 Million ≈ $55.33 Million |
+1242.99% |
| 2015-12-31 | CHF3.26 Million ≈ $4.12 Million |
-81.52% |
| 2014-12-31 | CHF17.63 Million ≈ $22.29 Million |
-56.47% |
| 2013-12-31 | CHF40.50 Million ≈ $51.21 Million |
+33.27% |
| 2012-12-31 | CHF30.39 Million ≈ $38.42 Million |
-1.37% |
| 2011-12-31 | CHF30.81 Million ≈ $38.96 Million |
-43.01% |
| 2010-12-31 | CHF54.07 Million ≈ $68.36 Million |
-21.30% |
| 2009-12-31 | CHF68.70 Million ≈ $86.86 Million |
-37.97% |
| 2008-12-31 | CHF110.75 Million ≈ $140.02 Million |
-10.36% |
| 2007-12-31 | CHF123.56 Million ≈ $156.21 Million |
+115.21% |
| 2006-12-31 | CHF57.41 Million ≈ $72.58 Million |
-30.32% |
| 2005-12-31 | CHF82.39 Million ≈ $104.17 Million |
-6.76% |
| 2004-12-31 | CHF88.37 Million ≈ $111.72 Million |
-- |
About Kuros Biosciences AG
Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Granules, an advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; Ma… Read more